Explore how GLP-1 agonists, originally for diabetes, could transform addiction treatment by reducing cravings.

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

(HealthDay News) — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published online in ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists often partially inform or misinform consumers.

The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduc ...

This cross-sectional study showed websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially informed and sometimes misinformed potential consumers. Compounded ...

GLP-1 agonists for weight loss are now commonly used for adults, but might they also be an effective treatment for younger ...

Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...